Top searches

PL

Resources

B2RLaw advises biotech company Ambulero on fundraising

27/01/2021

B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease on funding of up to USD 5.5 million received from from Orphinic Scientific.

As part of the investment, and with the help of B2RLaw, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.

Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. Buchanan, Randy Berholtz, Omaida C. Velazquez and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.

With offices in Palo Alto, California and Warsaw, Poland, Orphinic Scientific is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.

B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.

Szymon Syp advises, “We congratulate Ambulero and Orphinic Scientific on this transaction. Ambulero’s important work means that people that suffer from serious vascular disease (which at best, causes severe discomfort and at worst, can result in death) can live in comfort with the knowledge that innovative treatment is on the horizon. We wish Ambulero the best of luck on its future clinical testing”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

03/10/2022

Is Poland Up to the Task on Ukraine? Three Arguments For and Against

On whether Poland will be able to live up to its ambition of becoming a defense sector and Ukraine reconstruction […]

MORE
30/09/2022

European response to cyberwar. NIS-2 – an opportunity for increased levels of cyber security?

More than two months ago, on 13 July, after a political agreement was reached between the European Parliament and EU […]

MORE
26/09/2022

B2RLaw joins the EU VAT Expert Group

On September 12, the European Commission: Directorate-General for Taxation and Customs Union published a list of members of the VAT […]

MORE
22/09/2022

B2RLaw as an official legal advisor and partner of the Polish Paddle Tennis Federation

According to the wording of the agreement signed on September, 2022, the B2RLaw law firm has become the official and […]

MORE
09/09/2022

B2RLaw on INCBA Europe Cannabis Business Expo: 10-11 September 2022 in Zurich

Join us on the very first conference of lawyers active in the cannabis industry in Europe ever: INCBA Europe Cannabis Business […]

MORE
11/07/2022

B2RLaw advises early stage technology company The Village Network on financing received by a group of investors including Credo Ventures, 500 Startup and Tilia Impact Ventures

B2RLaw has once again advised The Village Network, the Polish company behind Wioski.co, which is run by three female entrepreneurs, […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close